Figure 11.

Association between plasma CXCL-12 and intimal hyperplasia (IH): CXCL-12 expression is thrombin and angiopoietin-2-dependent. (A) Plasma CXCL-12 (black filled) and migration inhibitory factor (MIF) (white filled) levels post-injury in wild-type (WT) recipients of WT (squares) or CD31-TFPI-Tg (circles) CD34+ cells. *Day 7 and day 28 p < 0.005 WT vs. CD31-TFPI-Tg for CXCL-12. p = NS for all comparisons of MIF. (B) CXCL-12 secretion by WTCD34+ cells (3 × 10⁴/well) after 24 h incubation with either PAR-1 antagonist (black bars), PAR-2 antagonist (white bars), or PAR-4 antagonist (gray bars) at the indicated concentrations for 30 min before addition of FVIIa with FX (both 10 nM) with or without prothrombin (4 nM) and FVa (6 nM) as indicated. All conditions performed in triplicate wells. Error bars indicate SEM. (C) Angiopoietin-2 secretion by WT CD34+ cells (3 × 10⁴/well) after 24-h incubation with PAR-1, -2, or -4 agonists at the indicated concentrations. All conditions performed in triplicate wells. Error bars indicate SEM. Data shown in (B,C) is from WT CD34+ cells. Abbreviations: Csi, control siRNA; Ang-2si, siRNA specific for angiopoietin-2. Experiments repeated at least twice.